利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

24 条记录 (耗时 0.011 秒)

    MOLECULAR DELIVERY VESICLE
    2.
    发明公开
    MOLECULAR DELIVERY VESICLE 审中-公开
    分子递送试剂盒

    公开(公告)号：EP2205264A1

    公开(公告)日：2010-07-14

    申请号：EP08800051.8

    申请日：2008-09-24

    申请人： THE UNIVERSITY OF QUEENSLAND

    发明人： PARTON, Robert Glenn ,  WALSER, Piers Jamie

    IPC分类号： A61K38/16 ,  A61K9/127 ,  A61K38/17 ,  A61K31/683 ,  A61K31/685

    CPC分类号： A61K31/683 ,  A61K9/127 ,  A61K9/1277 ,  A61K31/685 ,  A61K38/177 ,  A61K47/6919 ,  A61K47/6925 ,  A61K49/0043 ,  A61K49/008

    摘要： An isolated caveolin containing vesicle comprising a caveolin protein and at least one lipid, wherein at least about 30% of the at least one lipid is selected from phosphatidylethanolamine and phosphatidylglycerol is disclosed. Also disclosed is a method of making an isolated caveolin containing vesicle, an isolated caveolin containing vesicle comprising a recombinant caveolin protein, an isolated caveolin containing delivery vesicle, a method of making an isolated caveolin containing delivery vesicle and a method of treatment of a disease or condition by delivery of a molecule using the isolated caveolin containing delivery vesicle.

    摘要翻译： 公开了包含小窝蛋白蛋白质和至少一种脂质的分离的小窝蛋白囊泡，其中至少约30％的所述至少一种脂质选自磷脂酰乙醇胺和磷脂酰甘油。 还公开了制备含有分离小窝蛋白囊泡的分离小窝蛋白，包含重组小窝蛋白的分离小窝蛋白囊泡，含有分离小窝蛋白递送囊泡的方法，制备分离小窝蛋白递送囊泡的方法和治疗疾病的方法，或者 通过使用含有分离的小窝蛋白的递送囊泡递送分子的条件。

    THERAPEUTIC DELIVERY USING COMPOUNDS SELF-ASSEMBLED INTO HIGH AXIAL RATIO MICROSTRUCTURES
    5.
    发明公开
    THERAPEUTIC DELIVERY USING COMPOUNDS SELF-ASSEMBLED INTO HIGH AXIAL RATIO MICROSTRUCTURES 审中-公开
    治疗性给药使用高轴甚至能够共享组装CONNECTIONS微构造

    公开(公告)号：EP1146855A1

    公开(公告)日：2001-10-24

    申请号：EP99966656.3

    申请日：1999-12-21

    申请人： University of Washington

    发明人： YAGER, Paul ,  GELB, Michael, H. ,  LUKYANOV, Anatoly N. ,  GOLDSTEIN, Alex, S. ,  DISIS, Mary, L.

    IPC分类号： A61K9/00 ,  A61K9/127

    CPC分类号： A61K48/00 ,  A61K9/1274 ,  A61K47/6919

    摘要： Therapeutic complexes comprising plural therapeutic compounds self assembled into high axial ratio microstructures are described. The therapeutic complexes satisfy the formula HARM-Th, wherein HARM is a high axial ratio forming material and Th is a therapeutic coupled to or associated with the HARM. The therapeutic complexes also can satisfy the formula HARM- S- Th, wherein S is a spacer. Release of the therapeutic by the complex generally follows either 0-order kinetics or pseudo-first order kinetics. A method for delivering therapeutics to organisms, particularly humans, also is described. The method comprises administering an effective amount of (1) a ligand, such as a therapeutic, self-assembled into a HAR microstructure, or (2) a ligand, such as a therapeutic, coupled to or associated with a material capable of thereafter self-assembling into a high axial ratio microstructure, to the mammal. Nucleic acids are an example of a ligand that can be administered effectively according to this method through noncovalent attachment to the HARM-forming materials.